EICHORCondition: Advanced Breast Cancer · Sponsor: Stemline Therapeutics, Inc.
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
This description comes directly from the study's public registry record.
Stemline Trials · 1-877-332-7961 · clinicaltrials@menarinistemline.com
Always discuss trial participation with your own doctor first.
| Highlands Oncology Group | Springdale, Arkansas, United States | Recruiting |
| City of Hope | Duarte, California, United States | Recruiting |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | Recruiting |
| Stanford Cancer Center | Palo Alto, California, United States | Recruiting |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco, California, United States | Recruiting |
| UCLA Hematology Oncology - Parkside | Santa Monica, California, United States | Recruiting |
| Yale Comprehensive Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Advent Health Orlando | Altamonte Springs, Florida, United States | Recruiting |
| Sarah Cannon Research Institute at Florida Cancer Specialists | Orlando, Florida, United States | Recruiting |
| Florida Cancer Specialists & Research Institute (FCS) - Sarasota | Sarasota, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Winship Cancer Institute, Emory University | Atlanta, Georgia, United States | Recruiting |
+ 32 more locations — full list on the registry record.
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06638307